文献速递临床免疫分子诊断

基于免疫分析的血浆APOE4生物芯片分类新方法

Development of a new biochip array for APOE4 classification from plasma samples using immunoassay-based methods.
PubMed 文献 · Clin Chem Lab Med · 2018-01-01

该研究开发了一种基于生物芯片阵列技术的免疫分析方法,可在3小时内直接从血浆中同时检测APOE4和总APOE蛋白,通过计算比值判定E4等位基因状态。432份样本经PCR基因分型验证,奥地利和爱尔兰两中心分别正确分类170和262份样本,灵敏度和特异性均达100%。

要点

  • 生物芯片免疫法3小时内可直接从血浆判定APOE4状态。
  • 两中心共432份样本分类结果与PCR基因分型完全一致。
  • 该方法灵敏度和特异性均达100%,优于PCR基因分型。

核心结论

  • 化学发光生物芯片夹心免疫阵列可快速准确从血浆直接检测个体APOE4状态。

研究设计与样本

  • 研究采用生物芯片阵列技术,通过免疫分析同时检测血浆特异性APOE4和总APOE水平,共纳入432份样本,先经PCR基因分型,再由奥地利和爱尔兰两中心用BAT分类。

主要发现

  • 奥地利中心正确分类170份样本,爱尔兰中心正确分类262份样本,灵敏度和特异性均达100%。
  • 通过计算APOE4与总APOE蛋白比值,可将样本判定为E4等位基因阴性、杂合或纯合。

关键数值与推荐

  • BAT可在3小时内完成APOE4状态检测。
  • 432份样本中两中心分别正确分类170和262份,灵敏度和特异性均为100%。

临床怎么用

  • 该生物芯片平台可快速准确从血浆判定APOE4状态,有望替代PCR基因分型。
  • E4基因型已知影响多种疾病(包括阿尔茨海默病)的症状前风险、预后和治疗反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Apolipoprotein E (APOE) is a key player in lipid transport and metabolism and exists in three common isoforms: APOE2, APOE3 and APOE4. The presence of the E4 allelic variant is recognized as a major genetic risk factor for dementia and other chronic (neuro)degenerative diseases. The availability of a validated assay for rapid and reliable APOE4 classification is therefore advantageous. METHODS: Biochip array technology (BAT) was successfully applied to identify directly the APOE4 status from plasma within 3 h, through simultaneous immunoassay-based detection of both specific APOE4 and total APOE levels. RESULTS: Samples (n=432) were first genotyped by polymerase chain reaction (PCR), and thereafter, using BAT, the corresponding plasma was identified as null, heterozygous or homozygous for the E4 allele by calculating the ratio of APOE4 to total APOE protein. Two centers based in Austria and Ireland correctly classified 170 and 262 samples, respectively, and achieved 100% sensitivity and specificity. CONCLUSIONS: This chemiluminescent biochip-based sandwich immunoarray provides a novel platform to detect rapidly and accurately an individual's APOE4 status directly from plasma. The E4 genotype of individuals has been shown previously to affect presymptomatic risk, prognosis and treatment response for a variety of diseases, including Alzheimer's disease. The biochip's potential for being incorporated in quantitative protein biomarker arrays capable of analyzing disease stages makes it a superior alternative to PCR-based APOE genotyping and may deliver additional protein-specific information on a variety of diseases in the future.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Badrnya S, Doherty T, Richardson C, et al. Development of a new biochip array for APOE4 classification from plasma samples using immunoassay-based methods. Clin Chem Lab Med. 2018. PMID: 29220880. doi:10.1515/cclm-2017-0618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。